Kabi Brings In Reddy’s Rituximab As Biosimilar Breakeven Date Retreats

Indian Firm’s Rituxan Biosimilar Added Amid Pegfilgrastim Frustrations

 
• By Dean Rudge
  
high jump
Kabi is hoping soon to get over its pegfilgrastim hurdle • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products